A comparative study involving each chelating agent reported that the 64Cu-NODAGA PSMA ligand increased in vivo stability more than that increased by the PSMA formulation using DOTA and exhibited considerable tumor diagnosis ability, as indicated by the high tumor-to-background ratio [18]. The gene discussed is FOLH1; the disease is neoplasm.